methoxy polyethylene glycol-epoetin beta is the active ingredient of a drug marketed by hoffmann-la roche under the brand name mircera. mircera is a long-acting erythropoietin receptor activator (cera) indicated for the treatment of patients with anaemia associated with chronic kidney disease. it is the first approved, chemically modified erythropoiesis-stimulating agent (esa). mircera is supplied as a solution in pre-filled syringes for intravenous or subcutaneous administration. mircera was approved for use in europe in july 2007 by the european commission, in september 2007 by the swissmedic, and in november 2007 by the u.s. food and drug administration for use in the united states.